New progress in drug treatment of hyperkalemia in patients with chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2021.03.008

Abstract

Abstract:

Hyperkalemia is a common complication of chronic kidney disease, and its occurrence is often related to the decline of glomerular filtration rate, the application of renin-angiotensin-aldosterone system inhibitors, and especially combined application of the drugs as well as metabolic acidosis. The most commonly used oral drug for the treatment of hyperkalemia is cation exchange resin, whose traditional drug is polystyrene sulfonate, but its effectiveness and safety are still controversial. In recent years, new drugs such as patiromer and sodium zirconium cyclosilicate have been developed, and their potassium-lowering effect and safety are better than the traditional drugs, having become the effective drugs for the treatment of hyperkalemia.

Key words: Chronic kidney disease, Hyperkalemia, Polystyrene sulfonate, Patiromer, Sodium zirconium cyclosilicate

Jingru Bi, Yixuan Wang, Guangyu Zhou, Chen Wu, Shuojie Guo, Panpan Zheng. New progress in drug treatment of hyperkalemia in patients with chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(03): 162-165.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.03.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I03/162

References 35

[1]	Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives [J]. Lancet, 2013, 382(9888): 260-272.
[2]	Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease [J]. Arch Intern Med, 2009, 169(12): 1156-1162.
[3]	Weinberg JM, Appel LJ, Bakris G, et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy [J]. Arch Intern Med, 2009, 169(17): 1587-1594.
[4]	Seliger SL. Hyperkalemia in patients with chronic renal failure [J]. Nephrol Dial Transplant, 2019, 34(Suppl 3): iii12-iii18.
[5]	Belmar Vega L, Galabia ER, Bada da Silva J, et al. Epidemiology of hyperkalemia in chronic kidney disease [J]. Nefrologia, 2019, 39(3): 277-286.
[6]	Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis [J]. Adv Physiol Educ, 2016, 40(4): 480-490.
[7]	Coutrot M, Dépret F, Legrand M. Tailoring treatment of hyperkalemia [J]. Nephrol Dial Transplant, 2019, 34(Suppl 3): iii62-iii68.
[8]	Labriola L, Jadoul M. Sodium polystyrene sulfonate: still news after 60 years on the market [J]. Nephrol Dial Transplant, 2020, 35(9): 1455-1458.
[9]	Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age [J]. JAMA Intern Med, 2019, 179(8): 1025-1033.
[10]	Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study [J]. Am J Kidney Dis, 2012, 60(3): 409-416.
[11]	Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial [J]. JAMA, 2015, 314(2): 151-161.
[12]	李晓，徐钢，林洪丽，等. 聚苯乙烯磺酸钙治疗慢性肾脏病高钾血症患者的多中心临床研究[J]. 中华肾脏病杂志，2013, 29(6): 419-422.
[13]	Yu MY, Yeo JH, Park JS, et al. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients [J]. PLoS One, 2017, 12(3): e0173542.
[14]	Keng LT, Tsou PH. Unusual ileus due to calcium polystyrene sulfonate [J]. Postgrad Med J, 2016, 92(1091): 563.
[15]	Ribeiro H, Pereira E, Banhudo A. Colonic necrosis induced by calcium polystyrene sulfonate [J]. GE Port J Gastroenterol, 2018, 25(4): 205-207.
[16]	Li L, Harrison SD, Cope MJ, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia [J]. J Cardiovasc Pharmacol Ther, 2016, 21(5): 456-465.
[17]	Bushinsky DA, Spiegel DM, Gross C, et al. Effect of patiromer on urinary ion excretion in healthy adults [J]. Clin J Am Soc Nephrol, 2016, 11(10): 1769-1776.
[18]	Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors [J]. N Engl J Med, 2015, 372(3): 211-221.
[19]	Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia [J]. Kidney Int, 2015, 88(6): 1427-1433.
[20]	Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial [J]. Lancet, 2019, 394(10208): 1540-1550.
[21]	Ganesan C, Pao AC. Spironolactone plus patiromer: proceed with caution [J]. Lancet, 2019, 394(10208): 1486-1488.
[22]	Packham DK, Kosiborod M. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia [J]. Expert Opin Drug Metab Toxicol, 2016, 12(5): 567-573.
[23]	Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K⁺ selective ion trap [J]. PLoS One, 2014, 9(12): e114686.
[24]	Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial [J]. JAMA, 2014, 312(21): 2223-2233.
[25]	Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia [J]. N Engl J Med, 2015, 372(3): 222-231.
[26]	白婵，尚进，康冬，等. 环硅酸锆钠散对慢性肾脏病高钾血症患者短期降钾效果的临床观察[J]. 中华医学杂志，2020, 100(38): 2997-3000.
[27]	Nilsson E, Gasparini A, Arnlov J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system [J]. Int J Cardiol, 2017, 245: 277-284.
[28]	Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study [J]. Clin J Am Soc Nephrol, 2019, 14(6): 798-809.
[29]	Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study [J]. Nephrol Dial Transplant, 2021, 36(1): 137-150.
[30]	Fishbane S, Ford M, Fukagawa M, et al. A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia [J]. J Am Soc Nephrol, 2019, 30(9): 1723-1733.
[31]	中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J].中华肾脏病杂志，2020, 36(10): 781-792.
[32]	Davidson JP, King AJ, Kumaraswamy P, et al. Evaluation of the pharmacodynamic effects of the potassium binder RDX7675 in mice [J]. J Cardiovasc Pharmacol Ther, 2018, 23(3): 244-253.
[33]	Pitt B, Zann V, Roe C, et al. An evaluation of the pharmacodynamics, safety, and tolerability of the potassium binder RDX7675 [J]. J Clin Pharmacol, 2018, 58(8): 1035-1043.
[34]	Zann V, McDermott J, Jacobs JW, et al. Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate [J]. Drug Des Devel Ther, 2017, 11: 2663-2673.
[35]	Yu JG, Fan BS, Guo JM, et al. Anisodamine ameliorates hyperkalemia during crush syndrome through estradiol-induced enhancement of insulin sensitivity [J]. Front Pharmacol, 2019, 10: 1444.

Please choose a citation manager

Content to export